High intensity focused ultrasound (HIFU) is a noninvasive treatment modality that induces complete coagulative necrosis of a deep tumor through the intact skin. This study was conducted to analyze and evaluate the complications of HIFU for the treatments of hepatocellular carcinoma. A total of 59 patients with hepatocellular carcinoma, with a total of 72 lessions were enrolled in this study. Tumor size ranged from 2.5 to 14.0 cm in diameter, with a mean diameter of 7.6 cm. All patients had accepted HIFU treatment, and the median number of HIFU sessions was 1.32 per patient. Results: The common complications from HIFU therapy were skin burns of various grades (eight cases of grade 1 skin burns, 48 of grade 2, three cases of 3), and pain in the treatment regions (15 cases of mild pain, 37 cases of moderate pain, 7 cased of severe pain). Other systemic complications were relatively rare and included fever (5 cases), hypertension (8 cases), supraventricular tachycardia (3 cases), mild impairment of hepatic function (48 cases), and mild mpairment of renal function (2 cases). Local damage consisted of acute cholecystitis (2 cases), hematuria (6 cases ), cholangiectasis (5 cases), light pericardial effusion (2 cases), impairment of peripheral nerves (10 cases), pleural effusion in the right thorax (3 cases), and impairment of vertebral column (1 case). No gastric or intestinal tract perforation, big vessel rupture, or hepatic rupture occurred. Conclusions: HIFU is a minimally invasive treatment for patients with hepatocellular carcinoma; however, there are some systemic and local complications that should be taken into consideration in evaluating HIFU for therapeutic use.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common types of malignancy in humans and is also one of the most difficult types of cancer to cure (1). Surgical resection may be the first option for patients with HCC in order to cure or prolong their life. Unfortunately, because of multiple tumor nodules, vascular invasion, and accompanying advanced liver cirrhosis, surgical resection can be performed in only about 20% patients (2). Thus, nonsurgical treatments are usually the only available option for the majority of patients with HCC. These treatments include radiofrequency (3), microwave (4), laser (5), and cryosurgery (6).
High intensity focused ultrasound (HIFU) is a new treatment for solid malignant tumors that has emerged in recent years (7) (8) . Ultrasound beams can be focused and transmitted through solid tissues within body, causing heat effect and cavitation, which can destroy and coagulate deep tissues (9). HIFU coagulates lesions without surgical exposure or insertion of instruments, maintaining intake skin (10, 11). Significant progress in HIFU techniques was made for the treatment Technology in Cancer Research & Treatment, Volume 8, Number 3, June 2009 of solid tumors that were noninvasive, real-time monitoring, and conformal. In animal experiments and clinical reports, it was proved that HIFU can selectively destroy target primary or metastasis in liver (12) (13) (14) and other solid organs such as the kidney (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) .
Nevertheless, there are potential limitations for using HIFU to ablate tumor in liver. Ultrasound cannot propagate through air filled viscera (25), and it produces inevitable strong energy absorption at the ribs, which cause burn. Also, the reflection of HIFU, can cause deposition of the ultrasonic energy to anatomical positions other than the chosen target. Furthermore, the bio-effects of ultrasound especially its heat effect and cavitation can also damage tissues surrounding and overlying the target tumor as well as those tissues in the path of the ultrasound beam (26).
However, articles regarding the complications or side effects of HIFU for hepatocellular carcinoma are rare. Therefore, we herein focus on the complications experienced in a cohort of 59 patients with hepatocellular carcinoma who received HIFU treatment.
Materials and Methods

Patients
From September 2001 to September 2004, a total of 59 patients (51 men, 8 women, mean age 52 years, range from 32 to 76 years) with a confirmed 72 total hepatocellar carcinoma lesions underwent extracorporeal HIFU ablation. Each patient had no more than three lesions in their liver. Patients with widespread lesions were not suitable candidates for HIFU therapy and were excluded. The ethics committee at our university approved the study, and we received informed consent from each patient. All patients suffered from hepatitis of virus B concomitantly. Per the Child-Pugh classification system, (scored by hepatic encephalopathy, ascites, serum bilirubin, serum albumin, and prothrombin time) (27), there were 22 cases of grade A, 21 cases of grade B, 16 cases of grade C. According to the 6 th edition of the TNM (tumor-node-metastasis) staging system of the American Joint Commission for Cancer Staging (AJCC)/International Union Against Cancer (UICC), which focuses on tumor diameter, a solitary node, vascular or bile duct invasion, two patients corresponded to stage I, eight to stage II, 13 to III A , 36 to stage III B (28, 29) . According to the clinical classification system, 31 cases were of large masses, the other 28 cases were of nodule masses. Of the total 72 lesions, three were located in the caudate lobe, 17 cases were in the left external lobe, 16 were in the left internal lobe, 18 were in the right anterior lobe, 12 lesions were in the right posterior lobe, and 6 lesions were located beyond the two lobes. Among these patients, nine cases had a cancer embolus in the portal vein/ hepatic vein or bile duct as shown by computerized tomography (CT) or magnetic resonance imaging (MRI). Regarding of the maximal diameter of the target tumor mass, three cases were smaller than 3 cm, 15 cases were 3-5 cm, 17 cases were 6-10 cm, and 24 cases were larger than 10 cm. Total of 78 HIFU treatment sessions were executed for the patients with multiple lesions and large mass needing fractional or repeated HIFU treatment, because a single treatment last several hours and no more treatment time could be added for a general anesthesia patient. Among the 59 patients, 47 cases accepted transcatheter aterial chemoembolization (TACE) before HIFU for the target tumors that have an arterial sup-ply as shown by CT/ MR imaging. The other 12 cases with tumors lacking an arterial supply underwent HIFU treatment alone. Regular examinations and labs were conducted and taken on the patients such as blood and urine regular test, hepatic and renal function test, serum electrolytes test, electrocardiagraphy (ECG), X-ray, CT (CT Twin Flash scanner, Philips Co., Nitherland), or MRI (1.5-Tesla system, Sigma, General Electric, CV/I, USA) before and after HIFU. (The characteristic of all 59 patients are seen in Table I .)
HIFU Therapeutic System
The HIFU therapeutic system was designed by Chongqing Haifu Co. Ltd, (Chongqing, China). Briefly, as detailed previously (31, 32), the US beam was produced by a 12.6 cm diameter piezoelectric ceramic transducer with a focal length of 126 or 135 mm. In the center of the transducer, there was a 3.5 MHz diagnosis US scanner (AU3, Esaote, Italy), which was used for guiding to the target tissue. The diagnosis scanner and therapeutic transducer were moved in six directions with millimeter precision under computer control. The transducer was mounted in a water bag filled with degassed and distilled water. The acoustic pressure field at focal peak intensity varied from 5000 to 20,000 Wcm -2 (8) . The scanning speed ranged from 1 to 3 mm sec -1 . The treatment time with focused ultrasound varied from two to nine hours (median 5.3 hours) depending on the tumor size, location, depth, blood supply, and adjacent big vessels. Each pulse of HIFU lasted 20-30 seconds, and the interval between two continual pulses was about 10 seconds
HIFU Treatment
HIFU treatment was performed under general anesthesia with the patients lying in the supine position or on the right side so that a continuous focused US beam produced by the transducer can arrive at the target taking the path of shortest distance while maintaining skin integrity (7). The tumor mass was selected through the directional movement of the diagnostic scanner in the target region. The target volume included the tumor and the marginal healthy tissue, which was about 1.5-2.0 cm around the visible tumor.
Performed serial layer scanning of the tumor by real-time US and based on the images of each slice, the target regions were selected and ablated by transmitting HIFU pulse, focused ultrasound beams. Thus, complete coverage of the whole tumor volume was achieved t slice by slice. Before and after HIFU treatment, US of was taken.
Investigations of Complications
During HIFU treatment, the changes to the tissues through which the focused ultrasound beams passed, including the skin, hypodermis, and liver tissue as well as other surrounding organs, were monitored by real-time US only by investigating changes in the grey scales and echoes of the tissues. US was also used to monitored the surrounding or overlying tissues such as the gallbladder, pericardial sac, right kidney, gastrointestinal tract, et cetera. Continueous observations of vital signs and electrocardiography (ECG) were also taken during HIFU treatment.
Immediately after HIFU treatment, we had been monitoring vital signs and ECG readings for 3 hours, observed queried patient pain levels in the irradiated region, rechecked blood and urine values as well as hepatic and renal functions. Three days after HIFU, we observed any changes to the adjacent organs such as the exterior and interior hepatic bile duct, gallbladder, heart, right kidney, and right thoracic cavity by US. One month after HIFU, the patients were re-scanned of CT or MRI, in order to investigate the therapeutic effect of HIFU and changes to adjacent tissues, as well as vertebral column.
Define criteria of complications.
I. According to burn grading systems, erythematous burns corresponds to a grade1 burn, blister burns are grade 2, and deep burns are grade 3 (seen in Figure 1 ). II. Patients with mild pain (grade 1) did not need analgesia, those with moderate pain (grade 2) needed non-steroidal analgesia, and patients with severe pain required being morphine analgesia as needed. III. Elevated values of GPT and GOT beyond 40 U/L, or the elevated concentration of serum TBIL beyond 10 μmol/L, were considered markers of functional hepatic damage. IV. One time or persistent elevated serum creatinine concentration beyond 20 μmol/Lwas considered to represent renal damage. V. One time or persistent observation of more than 20 erythrocytes per visual field of microscopy in urine or gross hematuria were classified as hematuria.
VI. Tenderness in the gall bladder region, a positive
Murphy's sign, thickening of the wall of the gall bladder or an effusion surrouding the gall bladder on US were diagnosed as acute cholecystitis. VII. Pleural effusion or pericardial effusion present as a sonolucent space in US was considered a complication. VIII. Impairment of peripheral nerve sensation in the treatment region of the skin after HIFU was considered a complication. IX. Impairment of vertebrae was shown by moderately or high signal in T1 weighed imaging and moderately or low signal in T2 imaging by MR (median T1 and short T2). 
Results
Changes in Vital Signs and ECG During HIFU
Overall, five cases were experienced fever ranging from 37.5 ºC to 39.2 ºC. Two cases with tumors in the left liver lobe near the heart experienced supraventricular tachycardia, but recovered a normal rhythm soon after HIFU was discontinued.
Postoperative Complications
Changes in Vital Signs: Five patients experienced a fever below 38 ºC. Hypertension was found in eight patients and three patients were of supraventricular tachycardia were observed.
Pain in the Irradiated Region (Classified by International Standards):
All patients experienced pain in the HIFU treatment region. Fifteen patients reported mild, grade 1 pain that did not require analgesia, 37 patients reported moderate (grade 2) pain that required non-steroidal analgesia for relief, and seven patients reported severe pain that required morphine therapy.
Skin Burns
All 59 patients experienced skin burns of various degrees, mostly located on the skin in the path of the focused US; however, eight patients had skin burns located on the opposite side of the HIFU path. Eight patients reported erythematous burns (degree 1), 48 cases patients experienced a blister burn (grade 2), and 3 cases of deep burn were observed (grade 3, seen in Figure 1 ).
Impairment of Hepatic Function
After HIFU treatment, 48 cases of slightly elevated glutamicpyruvictransaminase (GPT) or glutamicoxalacetictransaminase (GOT) were noted, all of which were all below 80 units.
Impairment of Renal Function
Two cases of slight blood serum creatinine elevation were noted. Hematuria was observed in six patients, one of who experienced gross hematuria.
Damage of Gallbladder
Acute cholecystitis was diagnosed in two patients who displayed classic symptoms, including the typical ache and tenderness of the right upper abdominal quadrant (Murphy's sign), elevated numbers of total white blood cells and neutrophilic granulocytes in blood, thickening of the gallbladder wall and fluid surrounding the gallbladder on US.
Impairment of Bile Duct
US confirmed five cases of cholangiectasis of the hepatic bile duct. One of these patients presented with obstructive jaundice, as evidenced by yellow skin, and elevated total and direct serum bilirubin.
Impairment of Right Pleural Membrane
There were three cases of right thoracic pleural effusions after HIFU, which were identified by US and X-ray. These patients felt chest distress, thoracalgia, and shortness of breath after exercise. These symptoms dissipated or disappeared in about 2-3 weeks, which correlated with absorption of effusion fluid as evidenced by X-ray and US.
Pericardial Damage
Mild pericardial effusions were found in two cases whose target lesions were in the vicinity of the heart. These effusions were absorbed 4-6 weeks after HIFU treatment.
Impairment of Peripheral Nerves
Skin numbness at the treatment region was found in ten patients. After one year of neurotrophic drug treatment, none of these patients experienced any improvement in their numbness symptoms.
Impairment of Vertebral Column
One patient with a tumor in the right posterior lobe near the spinal vertebrae showed anomaly median T1 and short T2 weigh imaging in at the 12th thorax thoracic and 1st lumbar vertebrae taken on MRI. No severe complications such as gastric or intestinal perforation, big vessel rupture, or hepatic rupture were present.
The main complications of HIFU for HCC were shown in Table II .
Discussion
As a directed, focal, and non-invasive treatment for solid tumor ablation, HIFU can transfer energy to a targeted tissue and cause its destruction. The US wave is partially converted into heat energy, creating focal temperature increase to over 90 ºC (14). This thermal effect induces tissue and vessel damage by coagulative necrosis. With monitoring using real-time US, HIFU can be used for solid tumor conformal ablation. There are many clinical practices using HIFU for the treatment of solid tumors, including hepatocellular carcinoma, breast cancer, and osteocarcinoma in several hospitals around the world (30-33).
However, there is some inevitable heat diffusion out of the focal region and damage to surrounding tissue. Other bioeffects, such as cavitation (34), can also cause destruction of targeted and surrounding tissue. With real-time US, active and passive cavitation detection results show a strong correlation between the onset of cavitation and the appearance of a hyperechoic region, which maybe corresponse to the complications of HIFU. Passive cavitation showed that inertial cavitation typically occurred prior (within 0.5 s) to the appearance of a hyperechoic region. The observed cavitation activity confirms that bubbles are present during the formation of a hyperechoic region at the HIFU focus. Furthermore, due to the influence of the US, intracellular water may enter the gaseous phase. This would lead to the development of micro-bubbles. When they reach the size of resonance, these bubbles suddenly collapse and produce high-pressure shock waves, destroying adjacent tissue (34). And due to these bio-effects of US, as well as reflection, deflexion, and scattered radiation of the beam into non-targeted tissues, there are multiple complications associated with by HIFU treatment. Furthermore, because of the difference in bio-effects of US, heat sensitivity, and energy deposition between these target and adjacent tissues or organs, there are different side effects and complications in difference tissues or organs owing to HIFU treatment.
In our opinions, other factors also contribute to the complications of HIFU treatment for HCC. Firstly, the reflection of US by the ribs can cause deposition of US energy in skin and subcutaneous tissues, causing burns. Secondly, the absorption of HIFU energy can damage the tissues in the beam path as well as the adjacent tissues. Also, acoustic impedance differences can results in different distributions of energy within different tissues. Another complicating factor is the difference in heat sensitivity among tissues; for example, the heat effects of HIFU easily damage the electrocardiac conducting stem. Finally, as we know, hyperechoic region on in real-time US correlate well with necrosis during HIFU; however, we are unable to measure the exact temperature of HIFU focal region by US. Abnormally high temperatures create excess energy, which can cause side effects or complications. An MRI guided HIFU therapeutic system may enable real-time monitoring of the focal temperatures to avoid excess irradiation, reduce the ultrasonic energy and treatment time, decrease interval time of HIFU pulses, and also reduce complications.
In our study, we noted higher rates of complications than in other HIFU studies (26, 30, 36) . The extremely high incidence of complications from HIFU is not only associated with the fact that we were just beginning to develop HIFU treatment and lacked sufficient experience, but is also related to the physical characteristics (such as reflection, scattering, and refraction) and ultrasonic biological effects (cavitation effect, mechanical effect, etc.) of HIFU. Additionally, the high incidence of complications is also related to our clinical definitions of the complications. For example, with skin burns, a first-degree burn is defined as an erythematous burn mark, a blister burn is defined as a second-degree burn, and a deep burn is classified as third degree. Therefore, if any skin erythema occurs after HIFU, it is classified as a first-degree burn complication. Furthermore, if there is a certain amount of variation between preoperative and postoperative hematuria, hepatic function or renal function, the case is counted as having complications. If any pain occurs after HIFU, the patient is classified as having a complication. Also, we wish to point out that except for the three cases of third-degree burns, no severe complications were observed from our treatment protocol. The complications that occurred from HIFU therapy for liver carcinoma are associated with the physical characteristics and biological effects of ultrasonic waves, the anatomical characteristics of the liver, and effects of adjacent organs (such as the intestinal tracts and gas in the lung) and special tissues (such as cardiac conduction system, nerves).
The following discussions are the detail.
Thermal Injury
This was the most common complications due to ultrasonic energy deposition in the pathway of ultrasound, including skin and subcutaneous burns, muscle heat injury, and hepatic function impairment. Thermal injury caused by ultrasonic reflection. These complications usually occurred at the interface between tissues, with a drastic acoustic impedance difference that resulted in strongly energy absorption. Therefore, these traumas were located in the interface such as between air and skin, air and gastrointestinal tract, and gallbladder wall and peripheral gallbladder connective tissue. The bile duct, gallbladder, gastrointestinal tract, skin in the opposite side from the HIFU beam were also involved in thermal injury. Trauma in adjacent tissues or organs. These complications include right pleural effusions, pericardial fluid, damage to the right kidney, and hematuria.
Impairments in thermal-sensitive tissue such as nervous tissue and the electrocardic conducting stem occurred when targeting hepatic tumors located near the heart and ribs (intercostal nerve).
Systemic reactions of thermotherapy owed to US. These include fever during and HIFU treatment, elevation of blood creatinine, and hypertension. These changes were temporal and did not require intervention.
Skin and subcutaneous burns were found in all 59 patients enrolled in our study. These skin burns were mostly grade 1 and grade 2 skin burns, which recovered quickly with careful nursing and no special drugs. However, there were three patients with deep skin burns (grade 3) who needed immediate surgery for full-thickness resection and suture. Furthermore, one patient didn't recover from his burn recover until he was received a local flap graft to the burn site. To reduce or avoid skin burns, the power of HIFU during treatment could be reduced, the interval of consecutive ejecting of focused ultra-sound could be prolonged, or cold water cooling exposing skin in irradiated region could be done.
The other systemic and local complications, such as trauma to surrounding and overlying tissues, were relatively rare. The majority of patients needed no further special handling beyond accepted medical observations and symptomatic treatment.
Conclusively, local treatment with HIFU has a certain therapeutic effect, but its disadvantages are as follows: (i) the treatment time for HIFU is long, which increases the risks from anesthesia during the procedure; (ii) there are some highly reflective materials in the path of the HIFU irradiation such as the ribs, gas, the intestinal tract, big vessels, and the bile duct, which results in decreased eat from the HIFU directed into the target region and a lowering of the therapeutic effect of the procedure, all while potentially damaging tissue that lies in the irradiation path; (iii) the treatment time is so long that it runs the risk of inducing fatigue in involved medical staff, generally, treating a lesion of about 4 cm × 4 cm × 4 cm would spend about 8 hours (including anesthesia); (iv) other adjuvant treatment methods are required to improve the therapeutic effect, such as developing transarterial chemoembolization (TACE) before HIFU to decrease blood supply, percutaneous trans-hepatic local injection with lipiodol, partial rib resection to fully expose the treatment region and decrease rib reflection, developing an artificial right pleural effusion to expose the diaphragmatic dome and further treating the upper tumor in right hepatic lobe; and (v) there are multiple possible severe complications. We previously conducted HIFU treatment on 17 cases of recurrent and metastatic abdominal tumors, and observed some complications, including one case of whole enteric necrosis, which we published in World Journal of Gastroenterology (37) . The principal factors limiting the therapeutic efficacy of HIFU and causing complications in its use for live cancer are the interference of the ribs, sternum, intestinal tracts, and gas in the right lung, all of which lead to the loss of ultrasonic energy and damage to sites other than the one targeted. Although some experts propose to fully expose the ultrasound pathway by rib resection and fenestration for partial liver cancer in the right hepatic lobe, the majority of liver cancer cases selected for HIFU treatment are advanced or even terminal cases, thus the majority of patients did not want to undergo rib resection and fenestration. We presume that the most important factor for treating liver cancer with HIFU is proper case selection, specifically, small hepatocellular carcinomas in the left lobe, as carcinomas located in other regions of the liver cannot be treated as effectively by HIFU and experience more complications.
Compared with other treatment methods, the advantage of HIFU lies in its non-invasive and micro-traumatic character-istics. In order to promote the application of HIFU for the treatment of liver cancer and improve its therapeutic effect while decreasing complications, we hold that it is necessary to drastically improve the current HIFU therapeutic system. To carry out this improvement, we suggest the following: (i) minimize ultrasound emission to avoid the interferences of bones and gas; (ii) place the ultrasonic water bag (including probe) above the treatment couch to decrease patient movement at the progressive stage and allow better observation of staff during HIFU treatment; (iii) develop treatment probes with different focal lengths, to allow treatment of both superficial and deep liver cancers (such as liver cancer in the caudate lobe); (iv) develop a high-power probe, which would decrease treatment times and help in avoiding damage to regions adjacent to the target area caused by respiratory movement; (v) develop and apply a new real-time temperature monitoring system for the target region (such as MR) to replace the relatively subjective evaluation method of resorting to experience combined with grayscale ultrasound imaging, as well as to avoid excessive treatment and unnecessary complications; (vi) place an underwater video camera in the ultrasonic water bag to observe the change of local skin instantly.
Conclusion
As a non-invasive treatment, HIFU for patients with hepatocelluar carcinoma has systemic and local complications.
